Discover investment opportunities in Stocks For 1 Dollar using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks For 1 Dollar using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks For 1 Dollar using our Smart AI Filter.
8 stocks found for "Stocks For 1 Dollar"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.65 Risk measure | ±93.4% Price volatility | -1.0 Valuation | 0.00% Annual yield | |||
0.15 Risk measure | ±100.0% Price volatility | -0.2 Valuation | 0.00% Annual yield | |||
0.76 Risk measure | ±100.0% Price volatility | -0.1 Valuation | 0.00% Annual yield | |||
0.64 Risk measure | ±100.0% Price volatility | -0.4 Valuation | 0.00% Annual yield | |||
2.07 Risk measure | ±100.0% Price volatility | -4.2 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±71.0% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
1.11 Risk measure | ±100.0% Price volatility | — Valuation | 0.00% Annual yield | |||
1.01 Risk measure | ±72.3% Price volatility | -3.1 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
The heavy selling pressure might have exhausted for Senseonics (SENS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read moreDiscover why Zacks rates Healthcare Triangle as "Underperform", being the first on Wall Street to initiate coverage on the stock. Explore HCTI's heavy reliance on top clients amid liquidity issues and ongoing losses.
Read moreQ: How does GoPro (GPRO) perform in volatile markets?
A: GoPro is known for its high volatility due to its niche market and competitive consumer electronics sector. Historical data shows that stock prices can fluctuate significantly with market trends and product releases, suggesting a higher risk for conservative investors.
Q: What potential does Gevo Inc. (GEVO) have in the biofuels industry?
A: Gevo's focus on sustainable aviation fuels and isobutanol offers growth opportunities as demand for renewable energy sources rises. However, investors should consider the market's dependency on regulatory changes and fossil fuel price competitiveness.
Q: How does Chesapeake Energy (CHK) navigate oil and gas market cycles?
A: Chesapeake Energy operates in a cyclically sensitive industry, with revenues heavily tied to oil and gas price fluctuations. During downturns, the company may face financial strain, while upturns could enhance profitability, albeit with increased volatility.
Q: Is Akebia Therapeutics (AKBA) a stable investment?
A: As a biopharmaceutical company focused on kidney disease, Akebia's investment stability is contingent on drug approval processes, clinical trial outcomes, and the competitive landscape for kidney treatments.
Q: Does Plus Therapeutics (PSTV) offer attractive growth potential?
A: Plus Therapeutics' focus on drug development presents potential for growth if new therapies succeed. However, investors should weigh the risks associated with biotech's lengthy development timelines and regulatory requirements.
Q: What should investors know about Fortress Biotech's (FBIO) business model?
A: Fortress Biotech utilizes a unique financial model, acquiring and forming multiple subsidiaries in various therapeutic areas. This diversification could mitigate individual project risks but also complicates overall financial assessment.